Tryptase expression as a prognostic marker in patients with resected gastric cancer.
Published: 24th May 2017
Authors: C. Lin, H. Liu, H. Zhang, Y. Cao, R. Li, S. Wu et al.
Mast cells play important roles in the progression of various malignancies, but their prognostic value in gastric cancer is unknown. Tryptase expression, as an indicator of mast cell activity, was therefore evaluated to see whether this could be incorporated usefully into a prognostic nomogram after surgery in patients with gastric cancer.
Tissue microarrays from patients with gastric cancer were created from formalin‐fixed, paraffin‐embedded resection specimens. Tryptase density was assessed by immunohistochemistry, and the association between tryptase expression and prognosis was evaluated. Semiquantitative scoring was devised to determine an optimal cut‐off value that correlated with survival. A prognostic nomogram was then developed incorporating tryptase expression scores along with other variables known to be related to survival.
Tissue microarrays were generated from 419 patients having surgery for gastric cancer. Increased tryptase expression was associated with better overall and recurrence‐free survival (both
Tryptase expression is an independent prognostic factor for overall and recurrence‐free survival in patients with gastric cancer after surgical resection.Read more
You may also be interested in
Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Authors: S. D. Nelen, M. van Putten, V. E. P. P. Lemmens, K. Bosscha, J. H. W. de Wilt, R. H. A. Verhoeven et al.
Notes: Less surgery, more chemo, but no change in survival
Changes in treatment and outcome of oesophageal cancer in Denmark between 2004 and 2013. BJS 2017; 104: 1338-1345.
Authors: D. W. Kjaer, H. Larsson, L. B. Svendsen, L. S. Jensen
Notes: Better short‐term outcome
Randomized clinical trial
Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy. BJS 2017; 104: 1307-1314.
Authors: M. Scarpa, E. Pinto, E. Saraceni, F. Cavallin, M. Parotto, R. Alfieri et al.
Notes: Psychologists improve postoperative sleep
Adaptation of the By‐Band randomized clinical trial to By‐Band‐Sleeve to include a new intervention and maintain relevance of the study to practice. BJS 2017; 104: 1207-1214.
Authors: C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
Notes: Something to consider
Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. BJS 2017; 104: 1327-1337.
Authors: F. J. C. ten Kate, S. H. van Olphen, M. J. Bruno, B. P. L. Wijnhoven, J. J. B. van Lanschot, L. H. J. Looijenga et al.
Notes: Useful biomarker, especially for early disease
Authors: J. Thereaux, T. Lesuffleur, M. Païta, S. Czernichow, A. Basdevant, S. Msika et al.
Notes: Poor follow‐up despite international guidelines
Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. BJS 2017; 104: 1131-1140.
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
Notes: Only different in short term
Corrigendum: Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. BJS 2017; 104: 947-947.
Authors: J. M. Findlay, K. M. Bradley, L. M. Wang, J. M. Franklin, E. J. Teoh, F. V. Gleeson et al.
Preoperative imaging and prediction of oesophageal conduit necrosis after oesophagectomy for cancer. BJS 2017; 104: 1346-1354.
Authors: P. Lainas, D. Fuks, S. Gaujoux, Z. Machroub, A. Fregeville, T. Perniceni et al.
Notes: Vascular abnormalities may be causal
Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer. BJS 2017; 104: 1235-1243.
Authors: M. Bencivenga, G. Verlato, D.‐S. Han, D. Marrelli, F. Roviello, H.‐K. Yang et al.
Notes: Good performance
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. BJS 2017; 104: 1226-1234.
Authors: Z.‐X. Wang, G.‐X. Li, Z.‐W. Zhou, Z.‐P. Huang, F. Wang, R.‐H. Xu et al.
Notes: Facilitates individualized treatment